Delivery Order SPE2DB24D9144-SPE2DB25FCMLG
Award Date
2/27/25
Potential Completion Date
3/20/25
Potential Value
$14K
Federal Agency
Defense Logistics Agency
Awardee
DMS Pharmaceutical Group Inc.
Ultimate Awardee
Not listed
NAICS Category
424210 - Drugs and Druggists' Sundries Merchant Wholesalers
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract worth $7,679.34 to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract is for the supply of KADCYLA 100 MG VIALS and has an ultimate completion date of August 19, 2024. DMS Pharmaceutical Group is a key supplier in the federal pharmaceutical supply chain, providing a wide range of pharmaceutical products and medical supplies to the Department of Defense...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $18,033.54, is for the delivery of KADCYLA 160 MG VIALS, a specialized oncology medication, to support the medical supply needs of military healthcare facilities. The contract is not associated with any set-aside designation, allowing DMS Pharmaceutical Group...
This is a firm-fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is for the delivery of KADCYLA 160 MG vials, with a ceiling value of $41,039.20 and a period of performance through July 30, 2024. DMS Pharmaceutical Group holds a significant indefinite delivery contract (IDC) with the DLA, valued at up to $499,999,999, which runs through...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $24,623.52 contract is for the delivery of KADCYLA 160 MG vials, a cancer treatment medication, with a completion date of May 24, 2024. DMS Pharmaceutical Group holds a significant $499,999,999 indefinite delivery contract (IDC) with the DLA under the SPE2DB program, which allows the...
This is a firm fixed price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business. The contract has a potential value of $15,358.74 and is for the delivery of the pharmaceutical product KADCYLA 100 MG VIALS. The delivery order is part of a larger indefinite delivery contract between DMS Pharmaceutical Group and DLA that has a potential value up to $5 million through December 2025. This contract vehicle allows DLA to procure a...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $15,358.74 contract is for the supply of Kadcyla 100 mg vials, with a period of performance through August 28, 2024. DMS Pharmaceutical Group holds a large single-award indefinite delivery contract (IDC) with the DLA under the SPE2DB program, valued up to $499,999,999, which allows the...
This federal contract award, with ID SPE2DB22D9239|SPE2DB24FDJ06, was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $20,478.24 firm fixed-price delivery order is for the supply of KADCYLA 100 MG VIALS, with a period of performance through May 13, 2024. DMS Pharmaceutical Group Inc. holds a significant $499,999,999 indefinite delivery contract (IDC) with the DLA under the...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $13,327.42 contract is for the delivery of 160 mg vials of the oncology drug Kadcyla. The delivery order is part of a larger $499,999,999 Indefinite Delivery Contract (IDC) held by DMS Pharmaceutical Group with the DLA under the SPE2DB program, which enables the agency to issue...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $10,610.16, is for the delivery of KADCYLA 100 MG VIALS, a specialized pharmaceutical product. The contract has a firm fixed price pricing type and an ultimate completion date of March 17, 2025. DMS Pharmaceutical Group Inc. holds a significant single-award Indefinite...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $49,247.04, is for the delivery of KADCYLA 160 MG VIALS. It is a firm-fixed-price contract that does not have a set-aside designation. DMS Pharmaceutical Group Inc. holds a larger indefinite delivery contract (IDC) with the DLA, valued at up to $499,999,999, which runs through...